Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
暂无分享,去创建一个
P. Caliceti | G. Broggi | G. Maira | M. Ferrari | M. Cremonesi | G. Paganelli | G. Prisco | C. Grana | M. Chinol | M. Bartolomei | C. Grana | C. Sturiale | M. Gatti | M. Ferrari
[1] B. Wessels,et al. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis. , 2000, Cancer biotherapy & radiopharmaceuticals.
[2] H. Engelhard,et al. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. , 2000, Surgical neurology.
[3] P. Bondiau,et al. Up-front chemotherapy with fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. , 2000, European journal of cancer.
[4] M. Adamo,et al. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach , 2000, European Journal of Nuclear Medicine.
[5] F. D. De Braud,et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin , 1999, European Journal of Nuclear Medicine.
[6] H. Sakahara,et al. The relationship of glycosylation and isoelectric point with tumor accumulation of avidin. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] M. Ferrari,et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients , 1999, European Journal of Nuclear Medicine.
[8] J. Dempsey,et al. Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain-tumor resection-cavity margins. , 1998, International journal of radiation oncology, biology, physics.
[9] R. Coleman,et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Hopkins,et al. Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose. , 1998, International journal of radiation oncology, biology, physics.
[11] E. Oldfield,et al. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.
[12] L. Lopalco,et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. , 1991, Cancer research.
[13] A. Ahlbom,et al. BRAIN TUMOUR TRENDS , 1989, The Lancet.
[14] E. Oldfield,et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. , 1989, Journal of neurosurgery.
[15] R K Jain,et al. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.
[16] C. Meares,et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] H. Hoffman,et al. Extraneural metastases of central nervous system tumors , 1985, Cancer.
[18] A. Walker,et al. Epidemiology of brain tumors , 1985, Neurology.
[19] Fred H. Hochberg,et al. Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.
[20] D. Larson,et al. Radiotherapy of primary malignant brain tumors. , 1998, Seminars in surgical oncology.
[21] B. Fisher,et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. , 1992, International journal of radiation oncology, biology, physics.